PATENT ABSTRACTS 4535057 IMMUNOASSAY EMPLOYING MONOCLONAL HERPES SIMPLEX ANTIBODY AND BIOTIN-AVIDIN DETECTION SYSTEM Gordon Dreesman, Cynthia Kendallassigned to AMF Incorporated An immunoassay and kit for determining a viral antigen, such as herpes simplex. In one embodiment, the antigen is immunocaptured by an insoluble matrix presenting IgG antibody against the viral antigen. The matrix resulting is subscquently contacted by biotin labeled monoclonal IgM antibody and labeled avidin.
4536392 METHOD FOR CONTROLLING HEMOPHILIA IN MAMMALS Alan R Giles, Kenneth Mann, Kingston, MN, Canada assigned to Queen's University at Kingston A method for controlling HemophiliaA (Antihemophilic Factor (F. VIII:C) deficiency) in mammals is described. Factor VIII:C deficiency in the mammal is bypassed by infusion of a synergistic mixture of a phospholipid and Factor Xa so that the cascade process of blood clotting may continue. The proportions of phospholipid and Factor Xa in the mixture are critical Ks too little Xa has no effect while too much is toxic (thrombogenic). 4536476 STABLE EPIMERASE REAGENT, CYCLASE REAGENT AND RING EXPANSION REAGENT FOR CELL-FREE PRODUCTION OF CEPHALOSPORINS Saul Wolfe, Donal Westlake, Susan Jensen, Kingston, Canada assigned to Queen's University at Kingston Cyclase, epimerase and a ring expansion enzyme are isolated separately from a cell free extract of a prokaryotic beta-lactam producing organism to provide three separate and stable enzyme reagents for commercial production of cephaiosporins from peptide precursors. Isola-
335
tion is carried out by using ammonium sulfate, gel filtration and ion exchange chromatography. The enzymes may be immobilized on a suitable support and the production of cephalosporins may be carried out continuously. 4537768 COMBINED
VACCINE
Peter Apontoweil, Johannes A G Kok, EK Leersum, Netherlands assigned to Roussel Uclaf Combined, inactivated vaccine ready for administration and active against at least Newcastle disease and egg production drop caused by adeno-like viruses and process for the preparation of such vaccine by addition of (A) a Newcastle disease virus (NDV) containing liquid obtained by cultivation of a NDV, followed by inactivation of the liquid and optionally homogenizing it, together with (B) ad adeno-like virus (ALV) containing liquid obtained by cultivation of an ALV, followed by inactivation of the liquid and optionally homogenizing it, to an oil phase containing as essential components at least one of the components selected from the group consisting of light paratiinic mineral oils, vegetable oils and naphtenic mineral oils and one or more emulsifiers such as nonionic surface-active compounds derived from alkylene oxide and/or hexahydric alcohols and/or higher natural fatty acids such as esters or ester-ethers, optionally followed by homogenizing and/or addition of a preservative.
4537858 PLASTATIN Joseph O'Sullivan, Carol A Aklonis, Pushp Singh assigned to E R Squibb & Sons Inc Plastatin, an inhibitor of the enzyme phospholipase A2, can be prepared by cultivating Penicillium cbermesinum under submerged aerobic conditions.
4537859 PROCESS FOR PREPARING 3-HYDROXY-ML-236B DERIVATIVES KNOWN AS M-4 AND M-4' Akir Terahara, Minoru Tanaka, Hiromachi, Japan assigned to Sankyo Company Limited